Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CHRS

Coherus Oncology

CHRS Lead: Approved ★ Read the deep dive → 5 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $82.9M (Jun 30, 2026) ↓ 5 verdicts ↓
Oncology Protein

Market cap $119M 154.5M shares (10-Q, Jul 31, 2026) × $0.770 close Nov 6, 2026

Most recent annual filing: 2026-03-09

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Casdozokitug Ph2 topline2H 2026Casdozokitug Ph2 topline, 2H 2026, thesis-defining
  2. Tagmokitug + pasritamig Ph1 startFall 2026Tagmokitug + pasritamig Ph1 start, Fall 2026, routine
  3. UDENYCA corporate updateMar 31, 2027UDENYCA corporate update, Mar 31, 2027, routine
  4. Term B Loan corporate updateSep 1 – Apr 30, 2028Term B Loan corporate update, Sep 1 – Apr 30, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

TREGCHECK

Clinical development program platform evaluating tagmokitug (anti-CCR8 cytolytic antibody) across multiple solid tumor settings, including ESCC, HNSCC, gastric/GEJ/esophageal, and colorectal cancers; focused on CCR8-positive regulatory T cell depletion to overcome immune resistance

Targets: CCR8

Capital (as filed)

Cash
$82.9M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$22.4M Jun 30, 2026
Operating cash flow
−$62.1M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$105M cash, runway early October 2026 casdozokitug readout per the update of Aug 17, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Coherus Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-20 Watch Coherus Oncology (CHRS) — Scientific Deep Dive for LOQTORZI, Casdozokitug, and Tagmokitug Mid-2026 casdozokitug Phase 2 readout is the entire thesis; the risk/reward is asymmetric but the binary is unknowable, so the author recommends waiting for data rather than committing capital ahead of a 60%-drawdown-risk event.
  2. 2026-08-06 Speculative buy speculative UPDATE: Coherus Oncology (CHRS) - The Coin Flip Moved to October Enrollment is complete on the casdozo HCC Phase 2, the catalyst now has a named month (early October), and opex is genuinely shrinking, justifying a first tranche for investors with explicit binary-event risk tolerance sized to survive a 60% drawdown.
  3. 2026-08-17 Hold UPDATE: Coherus Oncology (CHRS) - They Funded the Coin Flip The $55M Innovatus debt facility removes the pre-readout dilutive equity raise risk, but the capital structure is now heavier with a senior IP lien and the equity is a levered stub behind secured debt, shifting risk/reward enough to step back from Speculative Buy to Hold for those still deciding.
  4. 2026-08-28 Hold UPDATE: Coherus Oncology (CHRS) - They Reloaded the ATM The new $50M Leerink ATM adds a dilution vector at management's discretion but does not change the scientific thesis or the October catalyst; the stance remains Hold for existing holders and the same levered-stub calculus applies for those still deciding.
  5. 2026-10-29 Hold UPDATE: Coherus Oncology (CHRS) - Tagmokitug Finally Shows Its Cards Tagmokitug's 6/8 response rate in 1L ESCC provides genuine proof-of-concept with denominators, but the cohort is tiny, the 2L HNSCC result missed the bar, and the story is not yet de-risked enough to change stance for either holders or sidelined investors.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)